Usefulness of the human papillomavirus DNA chip test as a complementary method for cervical cytology.
Biopsy
Cervix uteri
Human papillomavirus
Papanicolaou test
Journal
CytoJournal
ISSN: 0974-5963
Titre abrégé: Cytojournal
Pays: United States
ID NLM: 101231642
Informations de publication
Date de publication:
2023
2023
Historique:
received:
15
06
2020
accepted:
08
05
2022
medline:
9
10
2023
pubmed:
9
10
2023
entrez:
9
10
2023
Statut:
epublish
Résumé
As a convenient and economical method of screening cervical cancer and precancerous pathologies, the Papanicolaou smear (Pap smear) has been most widely used. Nevertheless, it requires cytological changes for making diagnoses and reportedly has a high false-negative rate. In this study, the usefulness of the human papillomavirus (HPV) DNA chip test as a complementary method that can compensate for the defect of the Pap smear was investigated. Of the 6516 patients who simultaneously underwent a Pap smear and an HPV DNA chip test at Chonnam National University Hospital between January 2015 and December 2016, 1897, an initial PAP smear-negative patients who had undergone an additional Pap smear during their 2-year follow-up period were selected for this study. Of the subject patients, 281 underwent a cervical biopsy. The Pap smear follow-up of an initial Pap smear-negative subjects showed 53 (75.7%) HPV high-risk positive cases in the cytology low-grade lesion group (70 cases) and 46 (97.8%) HPV high-risk positive cases in the cytology high-grade lesion group (47 cases). The 281 biopsy cases included 67 biopsy low-grade lesion cases and 74 biopsy high-grade lesion cases, of which there were 45 (67.2%) and 67 (90.5%) HPV high-risk positive cases, respectively. The follow-up cytology on the high-risk HPV-positive subjects showed that the ratio of their high-grade lesions was 260.8 times greater than that of the high-risk HPV-negative subjects (OR = 260.8 and 95% CI: 36.1 and 1886.1); and their biopsy showed that the ratio of their high-grade lesions was 102.7 times greater than that of the HPV-negative subjects (OR = 102.7 and 95% CI: 14.0 and 753.3). The complementary use of the HPV DNA chip test may be useful in increasing the accuracy of screening examinations for the early diagnosis of uterine cervix cancer when combined with the Pap smear.
Identifiants
pubmed: 37810438
doi: 10.25259/Cytojournal_40_2020
pii: 10.25259/Cytojournal_40_2020
pmc: PMC10559486
doi:
Types de publication
Journal Article
Langues
eng
Pagination
34Informations de copyright
© 2023 Cytopathology Foundation Inc, Published by Scientific Scholar.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interest.
Références
J Clin Pathol. 2002 Apr;55(4):244-65
pubmed: 11919208
Lancet Infect Dis. 2007 Jul;7(7):453-9
pubmed: 17597569
Clin Lab Med. 2000 Jun;20(2):257-70, v
pubmed: 10863640
N Engl J Med. 2007 Oct 18;357(16):1589-97
pubmed: 17942872
J Natl Cancer Inst. 2005 Jul 20;97(14):1072-9
pubmed: 16030305
Clin Obstet Gynecol. 1983 Dec;26(4):929-37
pubmed: 6661844
Am J Obstet Gynecol. 1974 Aug 1;119(7):953-8
pubmed: 4841153
Acta Cytol. 1991 Jan-Feb;35(1):8-14
pubmed: 1994641
JAMA. 1989 Feb 3;261(5):737-43
pubmed: 2642983
Lancet Oncol. 2010 Mar;11(3):249-57
pubmed: 20089449
J Natl Cancer Inst. 2003 Jan 1;95(1):46-52
pubmed: 12509400
Br J Cancer. 2000 Sep;83(5):561-5
pubmed: 10944591
Obstet Gynecol. 2004 Feb;103(2):304-9
pubmed: 14754700
Int J Cancer. 2010 Dec 15;127(12):2893-917
pubmed: 21351269
CA Cancer J Clin. 2011 Jan-Feb;61(1):8-30
pubmed: 21205832
J Natl Cancer Inst Monogr. 2003;(31):3-13
pubmed: 12807939
Lancet Oncol. 2005 Apr;6(4):204
pubmed: 15830458
Cancer Res. 2006 Nov 1;66(21):10630-6
pubmed: 17062559
Gynecol Oncol. 1997 Jul;66(1):108-13
pubmed: 9234930